1. Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

2. Pathological Mechanisms Underlying Vascular Changes in PH

5. Vasomotor Pathways Targeted by Therapies in PAH

6. Functional Class and Survival in PAH

7. NIH Registry: PAH Diagnosis (1981-1987)

8. French National Registry (2002-2003): PAH Still Often Diagnosed Late

9. Survival and PVR: Giessen PH Database

10. ESC/ERS Guidelines: Diagnostic Algorithm for PH

12. ESC/ERS Guidelines: Diagnostic Algorithm for PH (cont)

13. PAH Diagnostic Measures

14. PH Is Classified Into 5 Groups

15. Comprehensive Prognostic Evaluation and Risk Assessment Helps Guide Treatment

16. Initial Treatment of PAH

17. ESC/ERS Treatment Recommendations for Drug Monotherapy

18. Treat PAH as Aggressively as Possible

19. Functional Class II = Mild Disease?

20. Conflicting Evidence Regarding the Effectiveness of Combination Therapy in Short-Term RCTs

21. PAH Combination Therapies Tested in RCTs

22. ESC/ERS Recommendations for Sequential Drug Combination Therapy for PAH

23. Upfront Initial Combination Therapy

24. Initial Use of Ambrisentan Plus Tadalafil in PAH: The AMBITION Trial

25. AMBITION Trial: Primary Endpoint* Results

26. AMBITION Trial: Secondary Endpoint Results

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)

32. Abbreviations (cont)

33. Abbreviations (cont)